Introduction
A modern revolution in human genetics research began with the publication 10 years ago of the first edition sequence for the human genome [1, 2] . During the subsequent decade, major advances have occurred in the development of DNA arrays and high-density genotyping, parallel processing, next generation sequencing and bioinformatics. Clinical applications recently beyond reach are increasingly approachable, together with the promise that personalized medicine eventually can be translated from theory to practice [3 ,4 ] . The opportunity for the development of genomic strategies and tools for risk assessment, counseling and treatment planning are more compelling than ever before.
Genetic analysis has been an essential feature of clinical allogeneic hematopoietic stem cell transplantation (HCT) for more than nearly 40 years. Success in the early years and refinements in donor selection in the last few years have been based on a detailed understanding of the genetics of the human major histocompatibility complex (MHC) and the development of DNA-based methods for high-resolution genotyping of the highly polymorphic human leukocyte antigen (HLA) genes. Mismatching for HLA has an adverse effect on HCT outcome and increases risk of severe GVHD, graft rejection and mortality [5] [6] [7] [8] , and prolongs the duration of chronic GVHD [9] , while optimization of high resolution typing and allele-level donor and recipient HLA-matching has improved HCT outcome [10] . The role of non-HLA genes in generating alloimmune responses after HCT has been well defined for at least a few selected genes using T-cell clones, but little progress has been made in completing a catalog of these genes across the genome. In this review we address current knowledge
Genetic disparity and alloimmune response
Early pioneers in transplantation biology observed that genetic variation between individuals could induce immune responses in a recipient or donor and cause graft rejection or GVHD, and they hypothesized the existence of polymorphic genes encoding histocompatibility antigens capable of inducing both cellular and humoral immunity [11, 12] . The strongest histocompatibility antigens, also referred to as major histocompatibility antigens, are encoded by the class I and class II HLA genes of the MHC [11] . Although greater risk of GVHD and mortality is associated with HLA mismatching [5, 8] , clinically significant GVHD also occurs in HLA identical transplants, demonstrating that other genes in addition to HLA encode histocompatibility antigens [13] . The strength of these non-HLA or minor histocompatibility antigens may be relatively weak and they may activate only a limited number of T cells, but the overall response to minor histocompatibility antigens encoded throughout the genome can induce a polyclonal T-cell response capable of causing severe and life-threatening GVHD. The number of functional minor histocompatibility antigens present in any donor-recipient pair is undetermined, but most probably exceed the 25-30 currently known minor histocompatibility antigens by a 100-fold or more.
Minor histocompatibility antigens in related and unrelated donor transplants
Siblings share by common inheritance approximately 50% of all their genes, including those that encode minor histocompatibility antigens, while unrelated individuals share far fewer genes. Therefore, the burden of minor histocompatibility antigens disparity must be greater in unrelated compared to related donor transplants [14] .
Minor histocompatibility antigens and graft-versus-host disease
There have been several published studies that have tested different minor histocompatibility antigens for association with GVHD, however the results of these studies have been variable (summarized in a recent review by Warren in 2009) [15 ] . Although studies in HCT recipients as well as in-vitro studies have clearly demonstrated that minor histocompatibility antigen genes are capable of eliciting clonal T-cell responses, clinical association studies have been unable to consistently measure the individual effect of specific minor histocompatibility antigens on GVHD risk.
Y chromosome-associated histocompatibility antigens
In addition to the classical MHC and minor histocompatibility antigens, cellular proteins encoded by the Y chromosome can also induce an alloimmune response [16, 17] . Disparity for the Y chromosome occurs when male recipients receive HSC grafts from female donors (F ! M). The alloimmune response that follows is sufficiently strong to result in an increased risk of acute and chronic GVHD [9, [18] [19] [20] [21] [22] . The strength of the anti-Y response can be explained in part by the presence of several genes on the Y chromosome that are found in strong linked disequilibrium and which encode multiple male-specific epitopes (SMCY, UTY, DDX3Y, USP9Y, RPS4Y1, TMSB4Y and ZFY) that can elicit multiple CD4 þ and CD8 þ T-cell, and B-cell responses in F ! M HCT [16, 17, 19, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Structural polymorphisms and gene deletions
Another class of non-MHC genes affecting HCT outcome is illustrated by the recent study by McCarroll et al. showing that deletion of the entire UGT2B17 gene in the donor but not the recipient can result in an alloimmune response associated with acute GVHD [33 ] . This multicenter study initially examined six common deletions (UGT2B17, UGT2B28, GSTT1, GSTM1, LCE3C and OR51A2) in a phase I discovery study using 414 HLA matched related donor (MRD) transplants. The association of the UGT2B17 deletion with acute GVHD was validated in a phase II study of two additional cohorts with 336 and 595 HLA-identical sibling transplants, respectively. The odds ratio for the overall association was 2.5 (P ¼ 5 Â 10 À4 ) [33 ] . The cumulative incidence of grade 2-4 acute GVHD associated with the UGT2B17 deletion in the cohort of 595 matched sibling donor transplant recipients from our center is illustrated in Fig. 1 . The UGT2B17 gene is homozygously deleted in a variable proportion of every human population studied to date [34] . Several studies [35, 36, 37 ] have shown that HCT donors with homozygous deletion of UGT2B17 make CD8 þ UGT2B17-specific T-cell responses in recipients who express at least one copy of the gene.
Collectively, analysis of the effect of recipient incompatibility for MHC and non-MHC genetic disparity demonstrates that the risk of GVHD and mortality associated with different genes spans a wide spectrum. HLA disparity generally has a strong effect, disparity for individual minor histocompatibility antigen loci, for example HA-1, a much weaker effect, while disparity for the Y chromosome and the UGT2B17 deletion has an intermediate effect most likely because the latter encodes several distinct minor histocompatibility antigens. Although HLA restriction of T-cell responses is clearly defined for individual epitopes or peptides, larger blocks or segments of DNA such as that affected by the UGT2B17 deletion can alter multiple immune epitopes and potentially induce a broad immune response. Although T-cell responses to single peptides, measured individually, would be relatively weak, the more complex deletions and Y chromosome-encoded minor histocompatibility antigens are stronger and significantly contribute to clinical GVHD. The relative strength of these minor histocompatibility antigens is illustrated in Fig. 2 .
Genome-wide assessment of minor histocompatibility antigens disparity Ogawa et al. [38 ] have published a preliminary summary of their experience using a genome-wide association studies (GWAS) approach to measuring genome-wide disparity. They performed genome-wide single nuceotide polymorphism (SNP) scans for 1598 HLA-A, B, C, DRB1 and DQB1 matched unrelated patient-donor pairs, and measured SNP-by-SNP donor-recipient disparity across the genome under the assumption that there was no HLA restriction operating. The scan revealed a single relatively strong signal associated with grade 2-4 acute GVHD which mapped to the HLA-DP region with a maximum P value of 1.81 Â 10 À9 for SNP rs6937034. No other signals were detected under the assumption of no HLA restriction, but when the association analysis was limited to patients expressing HLA-DQB1Ã0601 a signal was detected on chromosome number 12 (rs17473423; P ¼ 3.99 Â 10 À13 ), and when the analysis was limited to patients expressing HLA-BÃ4403, another signal was detected on chromosome 9 (rs9657655; P ¼ 8.56 Â 10 À10 ) ( Fig. 3b and c) [38 ] . Overall, four additional loci were identified when the analysis was adjusted for restriction by DQB1Ã0501, CwÃ0102, B85201 and CwÃ1202.
Genetic variation affecting gene function, immune response and disease risk
In addition to the genetic variation that encodes disparity for HLA and minor histocompatibility antigens, many genetic polymorphisms are functional variants that affect gene transcription and translation, and protein structure. Most of the polymorphism in the human genome exists as SNPs. More than 13 million SNPs have been identified through massive resequencing by several laboratories participating in the 1000 genomes project (http://www. 1000genomes.org/page.php). Individual SNPs can be identified by various methods including PCR assays using specific primer pairs, and a million or more SNPs can be identified using DNA arrays.
Candidate gene studies
A candidate gene association study is usually the approach of choice when testing a specific hypothesis or replicating and confirming a prior study. This approach is generally efficient and cost effective when the task requires genotyping for one or a few dozen SNPs.
Genome-wide association studies
The advent of DNA array technology and parallel processing has allowed for simultaneous genotyping for a million or more SNPs [39, 40] and the development of dense SNP marker maps across the genome [39, [41] [42] [43] , making it possible to screen genes in an unbiased manner for polymorphisms that correlate with phenotype, disease status and relevant quantitative traits. As shown by multiple studies, the GWAS approach has been very successful in the discovery and identification of new genetic variation and genes associated with disease risk [44] . GWAS has uniquely contributed to the discovery of disease-associated genes in diabetes [45, 46] , rheumatoid arthritis [47, 48] and multiple sclerosis [49] by scanning the genomes of tens of thousands of individuals. A catalog of published GWAS results compiled by the US National Institutes of Health is available at www.genome.gov/ gwastudies.
Results from candidate gene association studies
Previous candidate gene studies have reported polymorphisms implicating at least 18 genes as associated with GVHD and mortality (specific genes, SNPs and associations summarized in Table 1 [50-74,75 ,76-80]). Results however have not always been consistent, and follow-up studies have often failed to confirm findings of previous studies. The reasons for these differences may be explained by heterogeneity among patient populations for race and clinical variables, but most likely failure to replicate these early studies reflects problems with statistical power and inadequate sample size. As an example, we discuss two genes that belong to the same pathway, IL10 and IL10RB.
The IL10 pathway and graft-versus-host disease
The IL10 gene has been the subject of several studies, and although results are not consistent, the cumulative evidence indicates that there is an IL10 effect in HCT outcome. Middleton et al. [66] were the first to report an association for an IL10-linked microsatellite polymorphism (À1064) with severe acute GVHD. This IL10 association with acute GVHD was expanded by the same group in a larger group of 144 MRD transplants to also include a SNP mapping to position À1082 in the IL10 5 0 promoter region (rs1800896). Socie et al. [56] analyzed three IL10 promoter region SNPs in 100 MRD transplants and identified an association with acute GVHD for a promoter region haplotype defined by three SNPs (À1082/À819/ À592).
We began our studies of the IL10 gene with a discovery phase analysis of two promoter region SNPs, À592 (rs1800872) and À1082 (rs1800896), in 570 MRD transplants, and showed an association of SNP À592 in the patient with severe acute GVHD and tranplant-related mortality (TRM) [60] . Following successful replication in an independent cohort of 423 MRD transplants, we combined the cohorts and in a subsequent analysis of the total 993 transplant recipients showed that the presence in the patient of the IL10/À592ÃAA genotype compared with the CC genotype was associated with both a decreased risk of grade 3-4 acute GVHD (HR, 0.4; P ¼ 0.02) and risk of nonrelapse mortality (HR, 0.6; P ¼ 0.05). A haplotype analysis showed that the IL10/ À592ÃA allele was a specific tag SNP for the promoter region haplotype T-C-A-T-A (SNPs at positions À3575, À2763, À1082, À819 and À592) [60] .
Results of other studies of IL10 gene, however have been variable and often contrary. Rocha significant association of IL10/À1082 with chronic GVHD in 107 HLA MRD transplants, but no significant association with acute GVHD or TRM. Mullighan et al. similarly found a significant association of the À592/ À819/À1082 haplotype in the patients with chronic GVHD in 160 MRD transplants, but no significant association with acute GVHD or TRM [54] . Sivula et al. [70] found an association of the patient IL10/ À592ÃAA genotype with an increased risk of acute GVHD in 309 MRD transplants, an effect opposite to that reported by Lin et al. [60] . Keen et al. [68] analyzed the IL10 gene in unrelated donor transplants and found an association of an extended haplotype consisting of the microsatellite marker IL10R2 together with the À1082/ À819/À592 IL10 promoter region SNPs associated with an increased risk of TRM. A study of IL10 promoter region SNPs in 936 unrelated donor transplants at our center, however, failed to show any significant association with GVHD or TRM [69] .
We have extended the genetic analysis of the IL10 pathway in GVHD to include the IL10RB gene encoding one of two IL10 receptors. We genotyped for a SNP at cDNA position 238 in exon 2 of the IL10RB gene (rs2834167) that is known to regulate the expression of the IL10 receptor [81] . The presence of the IL10RB/ c238ÃG allele in the donor was significantly associated with a lower risk of grades III-IV acute GVHD in MRD transplants, and a synergism was observed between IL10/ À592ÃA and IL10RB/c238ÃG in reducing the overall risk of acute GVHD [71] . More recently, Sivula et al. [70] have reported a comparable effect for the c238 SNP with an association of the ÃAA genotype with an increased risk of acute GVHD in MRD transplants albeit in the patient and not the donor genome. The inconsistency of the results for IL10 as detailed in this preceding section almost certainly apply to the other genes listed in Table  1 . A more clear understanding and definitive analysis of the genetics of GVHD will require much larger population studies appropriately stratified to control for racial admixture and adjusted for clinical covariates that may be confounding the overall results.
Genome-wide association studies in hematopoietic stem cell transplantation
Preliminary results from two GWAS-HCT projects related to HCT have been published. Ogawa et al. [38 ] are performing a GWAS of unrelated HCT patient-donor pairs transplanted through the Japanese Marrow Donor Program, and our group has embarked upon a GWAS of GVHD and other HCT outcomes including opportunistic infection and organ specific complications [82 ] . From 3177 patients undergoing HCT at our center between 1992 and 2005 for whom DNA was available, we randomly selected a discovery cohort of 488 Hematopoietic stem cell transplantation Holler et al. 1560 donor-patient pairs (total of 3120 samples), and reserved the remainder patient-donor pairs as the validation cohort. Samples were genotyped using the Affymetrix GeneChip Genome-Wide Human SNP Array 5.0, which contains over 500 000 SNPs placed evenly across the genome.
Following the GWAS convention, we assessed SNPallelic and genotypic associations with each of multiple clinical phenotypes. In the GWAS community, a generally accepted significance level is a P-value of 10 À8 (equivalent to the P-value of 1% with Bonferroni correction for 1 million SNP comparisons). Since the significance level is influenced by linkage-disequilibrium structure, we performed 1000 permutations on our own genome-wide data, and established the significance threshold by controlling the average number of false discoveries to be less than 1 under the genome-wide null hypothesis, resulting in a P-value of 10 À6 as the threshold for significance in our cohort. With this criterion, we identified 65 SNPs among 12 HCT phenotypes as candidates for the replication studies ( Table 2) . As described by Chien et al. [82 ] the Gram-negative bacteremia GWAS results have been tested for replication. Of the nine SNPs found to be significant in the initial GWAS, all in the genome of the patient, one was successfully replicated. Prompted by this disappointing finding, we re-examined the prior power estimations and explored the potential advantages of expanding the size of the phase I discovery analysis. We thus considered how the power for discovery might be affected by a 2.5-fold increase in sample size. Figure 4 shows the power curves for detecting dominant genetic associations with minor allele frequencies (MAF) of 10 and 25%, when the sample size is 1500 (black) and 4000 (grey lines). Increasing sample size uniformly improves power across a range of odds ratios from 1.2 to 2.0 (which is equivalent to a hazard ratio in a time-to-event analysis under rare disease Allogeneic hematopoietic stem cell transplantation Hansen et al. 489 assumption). Thus, it should be possible to achieve a more than doubling of the study power for detecting odds ratios of 1.5 across different allelic frequencies in the expanded cohort with a 2.5-fold increase in sample size. The improvement in power is even greater for an odds ratio ranging from 1.5 to 1.8, and power is also improved for lower incidence rates in the range of 10%. These power calculations suggest that expanding the sample size from 1500 to 4000 cases as proposed should increase sensitivity and power for discovery and thereby broaden the ultimate utility of this dataset by identifying additional genetic variants that may be missed in the current study and yet are clinically meaningful.
Conclusion
Candidate gene studies performed to date have been far from conclusive and were largely limited in sample size, but they have nonetheless provided compelling evidence that genetic variation in the donor and patient can affect transplant outcome. Definitive utilization of GWAS and more adequately powered studies will require extensive multicenter participation, resources to prospectively collect pretransplant DNA, uniform eligibility requirements, standardized definition of clinical phenotypes and informed consent appropriate for performing genome-wide genetic studies. Achieving complex studies like this in the future will also require the careful planning, discipline and funding provided by large cooperative clinical trials.
